Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19

Insel Gruppe AG, University Hospital Bern620 enrolled

Overview

Prospective Observational Swiss Cohort Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19.

COVID-19 is a coronavirus induced viral pneumonia leading to Acute Respiratory Distress Syndrome. Previous coronavirus infections (SARS and MERS) led to pulmonary fibrosis in up to 30%. Prospective evaluation of lung abnormalities and pulmonary fibrosis after COVID-19 infection is crucial as novel treatments against lung fibrosis of different etiologies are available. No data on pulmonary longterm effects in COVID-19 survivors are currently available. The nation-wide Swiss COVID-19 lung group establishes a meticulously characterized prospective cohort study on pulmonary long-term sequela of patients living in Switzerland.

Study Type

OBSERVATIONAL

Enrollment

620

Conditions

COVID-19

Interventions

COVID-19OTHER

Research project in which biological material is sampled and health-related personal data are collected and used for further research. Coded data are used.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed written informed consent. * All adult patients with COVID-19 over 18 years. Exclusion Criteria: * Severe mental or physical disability precluding informed consent or compliance with the protocol for prospective data collection. * Pregnancy.

Locations (9)

St. Claraspital AG - Department of Pulmonary Medicine

Basel, Switzerland

Universtiy Hospital Bern (Inselspital), Department of Pulmonary Medicine - Lead Center

Bern, Switzerland

University and Hospital of Fribourg

Fribourg, Switzerland

Outcomes

Primary Outcomes

Pulmonary follow-up sequelae in patients after COVID-19

Number of patients with the long-term pulmonary complications by measuring lung function, exercise testing and radiological Imaging

Time frame: 36 months

Evaluation of risk factors for adverse Outcome after COVID-19

Number of patients with risk factors including comorbidities and other cofactors and correlate them to adverse outcome in patients after COVID-19

Time frame: 36 months

Secondary Outcomes

Compare the functional Pulmonary outcome of COVID-19 disease

Compare pulmonary function measurements between mild and moderate to severe and critical COVID-19 disease

Time frame: 36 months

Compare the radiological Pulmonary outcome of COVID-19 disease

Compare imaging measurements between mild and moderate to severe and critical COVID-19 disease

Time frame: 36 months

Quality of Life after COVID-19

Compare Quality of Life questionnaires between mild and moderate to severe and critical COVID-19 disease

Time frame: 36 months

Physical performance after COVID-19 using Clinical Frailty Scale

To observe and compare the physical performance after COVID-19 via the Clinical Frailty Scale between mild and moderate to severe and critical COVID-19 disease

Time frame: 36 months

Physical performance after COVID-19 using frailty assessment tests

To observe and compare the physical performance after COVID-19 via frailty assessment tests between mild and moderate to severe and critical COVID-19 disease

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.